WaveMan · Form 4
Baker Julian insider trades
> Search tickers & screens ⌘K
LIVE

Baker Julian insider trades

Baker Julian has filed 22 Form 4s with the SEC that we hold, for IGMS (Director, 10% owner), Kiniksa Pharmaceuticals International, plc (KNSA) (Director), Madrigal Pharmaceuticals, INC. (MDGL) (Director) and Incyte Corp (INCY) (Director, 10% owner), among 13 companies in all. Across all of them we count 31 purchases worth $126.9M and 6 sales worth $1.2M reported on Form 4. None of these purchases or sales is dated in the last 12 months. The largest single trade was a purchase of 772,751 shares of Incyte Corp worth $52.2M, dated 2022-02-10. The first filing on our record is dated 2022-02-14 and the latest 2026-06-29.

IGMS

Director, 10% owner · 3 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Kiniksa Pharmaceuticals International, plc (KNSA)

Director · 3 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Madrigal Pharmaceuticals, INC. (MDGL)

Director · 3 filings · 24 purchases and sales
Trade dateCodeSharesValue as filedFiled
2023-11-14P, purchase reported on Form 42,658$415.8K2023-11-15
2023-11-14P, purchase reported on Form 431,530$4.9M2023-11-15
2023-11-15P, purchase reported on Form 41,181$191.3K2023-11-15
2023-11-15P, purchase reported on Form 414,018$2.3M2023-11-15
2023-11-21P, purchase reported on Form 4176$33.0K2023-11-21
2023-11-21P, purchase reported on Form 41,385$258.4K2023-11-21
2023-11-21P, purchase reported on Form 4388$72.7K2023-11-21
2023-11-21P, purchase reported on Form 44,712$882.4K2023-11-21
2023-11-21P, purchase reported on Form 41,076$202.6K2023-11-21
2023-11-21P, purchase reported on Form 413,011$2.5M2023-11-21
2023-11-21P, purchase reported on Form 41,117$210.5K2023-11-21
2023-11-21P, purchase reported on Form 413,505$2.5M2023-11-21
2023-11-21P, purchase reported on Form 41,291$243.6K2023-11-21
2023-11-21P, purchase reported on Form 415,620$2.9M2023-11-21
2023-11-21P, purchase reported on Form 4655$124.5K2023-11-21
2023-11-21P, purchase reported on Form 47,917$1.5M2023-11-21
2023-11-21P, purchase reported on Form 412$2.2K2023-11-21
2023-11-21P, purchase reported on Form 4146$27.1K2023-11-21
2023-11-21P, purchase reported on Form 431$5.7K2023-11-21
2023-11-21P, purchase reported on Form 4369$67.6K2023-11-21
2023-11-21P, purchase reported on Form 453$9.9K2023-11-21
2023-11-21P, purchase reported on Form 4647$120.5K2023-11-21
2023-11-21P, purchase reported on Form 4115$21.5K2023-11-21
2023-11-21P, purchase reported on Form 42,124$397.7K2023-11-21

Incyte Corp (INCY)

Director, 10% owner · 2 filings · 7 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-02-10P, purchase reported on Form 4772,751$52.2M2022-02-14
2022-02-10P, purchase reported on Form 440,164$2.7M2022-02-14
2022-02-10P, purchase reported on Form 46,100$409.9K2022-02-14
2022-02-11P, purchase reported on Form 4265,522$17.7M2022-02-14
2022-02-11P, purchase reported on Form 410,985$735.4K2022-02-14
2022-02-14P, purchase reported on Form 4320,526$21.2M2022-02-14
2022-02-14P, purchase reported on Form 4182,326$12.0M2022-02-14

Prelude Therapeutics Inc (PRLD)

Director, 10% owner · 2 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

vTv Therapeutics Inc. (VTVT)

Director · 2 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Acadia Pharmaceuticals INC (ACAD)

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

BCEL

Reporting owner · 1 filing · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2023-10-19S, sale reported on Form 422,837$9.1K2023-10-23
2023-10-19S, sale reported on Form 4251,902$100.8K2023-10-23

Bicycle Therapeutics PLC (BCYC)

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

DBV Technologies S.A. (DBVT)

Director · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Denali Therapeutics Inc. (DNLI)

Director · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

KALA BIO, Inc. (KALA)

Reporting owner · 1 filing · 4 purchases and sales
Trade dateCodeSharesValue as filedFiled
2025-09-30S, sale reported on Form 421,376$34.2K2025-10-02
2025-09-30S, sale reported on Form 4195,425$312.7K2025-10-02
2025-10-01S, sale reported on Form 4462,967$638.9K2025-10-02
2025-10-01S, sale reported on Form 450,640$69.9K2025-10-02

SGEN

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1087939) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms